Canada's Voice For
Biotechnology
Members
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.icotherapeutics.com |
| Contact: |
Andrew Rae (rae@icotherapeutics.com)
1 604 6029414
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): ICO.V |
| Description: |
iCo Therapeutics is an emerging biotech company focused on the identification, development and commercialization of drug candidates that treat sight and life threatening diseases through a development-only business model. |
| Location: |
Halifax, Nova Scotia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.imvaccine.com |
| Contact: |
John Trizzino (info@imvaccine.com)
1 902 4921819
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): IMV |
| Description: |
Immunovaccine Inc. applies its novel adjuvanting platform, DepoVaxTM, to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company’s platform technology is a formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. The DepoVax platform is a combination of antigens, immune enhancers formulated in liposomes, and then in oil. This patented combination raises unusually strong and long lasting cellular and/or humoral immune responses, which allow the company to create effective, single dose vaccines. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious disease pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Pfizer Animal Health. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
imstartx.com/ |
| Contact: |
(info@imstartx.com)
|
| Description: |
ImStar Therapeutics are developing a breakthrough new approach to treat patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. By exploiting a major new biological target behind the underlying disease, the company expects to make great strides in treating this devastating neurological condition and other related neurodegenerative disorders such as Dementia, Alzheimer's Disease and Parkinson's Disease. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.indelrx.com |
| Contact: |
Malcolm Kendall (mkendall@indelrx.com)
1 604 5518464
|
| Description: |
Indel Therapeutics Inc. is a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs that focus on curing difficult-to-treat and hospital-acquired infections. These programs are based on Indel’s paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of bacterial and parasitic infections and, potentially, fungal and viral infections. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.ixsbio.com |
| Contact: |
Jeff Morhet
1 480 8627500
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): IXS.V |
| Description: |
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus. |
| Location: |
New Glasgow, Nova Scotia |
| Industry Sector: |
Biotechnology / R&D Services |
| Website: |
www.innovascreen.com |
| Contact: |
Jeff Skinner (jeff.skinner@innovascreen.com)
1 902 482 3832
|
| Description: |
Innovascreen's proprietary platforms accelerate pre-clinical development through advanced screening technologies or enhanced drug delivery. With two proprietary platforms, the ASET Platform for early preclinical research and the Fusogenix Platform for drug delivery, Innovascreen has the tools to accelerate an important stage of the development process. Whether combined with internal programs or partnered with external compounds, these platforms have the opportunity to add significant value to preclinical therapeutic opportunities. |
| Location: |
Charlottetown, Prince Edward Island |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.innovationpei.com |
| Contact: |
Cheryl Paynter (clpaynter@gov.pe.ca)
1 902 3686300
|
| Description: |
Innovation PEI is focused on advancing economic development in Prince Edward Island by investing in people, innovation, and infrastructure. They are targeting key sectors, aerospace, bioscience (including agriculture and fisheries), information technology, financial services and renewable energy. They strive to assist the rapid development of these sectors and others to drive their Island economy through innovative new products and services. |
| Location: |
Burnaby, British Columbia |
| Industry Sector: |
Biotechnology / R&D Services |
| Website: |
www.innovativetargeting.com |
| Contact: |
Michael Gallo (mgallo@innovativetargeting.com)
1 604 433 6779
|
| Description: |
Innovative Targeting Solutions Inc. (InnoTarg) is focused on the development of novel human antibody technologies. ITS' platform is capable of "de novo" antibody generation; and, for the first time, allows for mammalian display repertoires of >10^9 to be exploited effectively. |
| Location: |
Montreal, |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.insymbiosis.com |
| Contact: |
(info@insymbiosis.com)
1 514 8079315
|
| Description: |
InSymbiosis is a drug development company that leverages their unique "drug development engine" that uses a functional outsourcing approach combined with their ability to secure funding in order to enter into either risk-shared or fee for service relationships with their international biopharma partners. Their drug development engine enables us to provide highly customized drug development capabilities to the global biopharma industry. Founded in 2005 in Montreal, Canada, InSymbiosis has a proven track record of supporting both small biotech and big pharma companies. InSymbiosis provide a “one-stop-shop” model where they offer an enabling and integrated approach for discovery, bioanalysis/analysis, drug safety assessment, chemistry, manufacture and control and clinical development. Their speciality is transitioning drug development candidates from preclinical to human clinical proof of concept and beyond across most therapeutic areas. What makes us further unique is their ability to provide their partners with dramatic cost saving solutions through their leveraging of a variety of novel cost reduction strategies. At the same time, their attention to scientific integrity, quality and regulatory compliance ensures that the programs executed in collaboration with InSymbiosis withstand the rigours of regulatory authority scrutiny and investor due diligence. The result, InSymbiosis delivers a truly unique, game changing drug development solution to the biopharma industry where they can work under unique risk-shared or fee for service structures. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Medical Technology |
| Website: |
interfacebiologics.com |
| Contact: |
Thomas P. Reeves (information@interfacebiologics.com)
1 416 673 8170
|
| Description: |
Interface Biologics Inc. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Their primary focus areas are anti-thrombogenic additives using their Endexo™ technology platform and programmable combination drug delivery devices using our Epidel™ and Kinesyx™ technology platforms. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.iricor.ca |
| Contact: |
Steven J. Klein (info@iricor.ca)
1 514 343 6647
|
| Description: |
IRICoR is the commercialization arm of the Institute for Research in Immunology and Cancer (IRIC) at Université de Montreal (UdM). Their mission is to accelerate the translation of commercially-relevant IRIC research into therapeutic drug candidates in oncology, immunovirology and related therapeutic fields. Founded in 2003, scientists at IRIC have developed a unique collection of technological platforms and gathered the expertise that has allowed for the establishment of an integrated discovery unit that encompasses target identification, preclinical proof of principle, and early clinical studies. IRICoR’s principal mandate is to create value for highly innovative projects developed by IRIC/UdeM and their partners by commercializing the most advanced projects in its pipeline. To do this, IRICoR strategically supports and invests in selected projects to rapidly transition them from the academic environment to the market, while ensuring the identification of the best partners for development and financing. IRIC also has developed an impressive array of technology platforms, including genomics (full genome sequencing and analysis), shRNA HTS (genome wide), high throughput histopathology (resident pathologist, tissue array), cytology and tissue banks (resident cytogeneticist), FACS (HTS capacity), proteomics (quantitative mass spectrometry), bioimaging, bioinformatics, identification and optimization of chemical tools/leads, Medicinal Chemistry, PK-ADME (in vitro and in vivo), biophysics (NMR), and target validation. As well, IRIC is home to one of Canada’s largest animal facility and includes transgenesis capabilities. IRICoR has developed a portfolio of highly innovative projects in these fields which are mainly at the stage of lead identification and optimization. They are seeking partners who would be interested in accessing their project portfolio via licensing or collaborative research agreements (or other approaches) for further development. Examples of the projects currently funded by IRICoR include inhibitors of Polo kinase, modifiers of estrogen signalling, biosensors for the real-time monitoring of receptor-mediated G protein activation, and regulators of hepatic cancer stem cells. |
